Latest filings (excl ownership)
10-K
2023 FY
Annual report
29 Feb 24
8-K
Maravai Lifesciences Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Maravai Lifesciences Reports Third Quarter 2023 Financial Results
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Maravai Lifesciences Reports Second Quarter 2023 Financial Results
7 Aug 23
8-K
Maravai LifeSciences Announces Completion of Planned CEO Leadership Transition
27 Jul 23
8-K
Maravai LifeSciences Announces Appointment of New Director to the Board
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
22 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Maravai Lifesciences Reports First Quarter 2023 Financial Results
8 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
DEF 14A
Definitive proxy
20 Apr 23
8-K
Departure of Directors or Certain Officers
13 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Maravai Lifesciences Reports Fourth Quarter and Full Year 2022 Financial Results
22 Feb 23
8-K
Maravai LifeSciences Announces Updated CEO Leadership Transition Plans
1 Dec 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Maravai Lifesciences Reports Third Quarter 2022 Financial Results
2 Nov 22
8-K
Departure of Directors or Certain Officers
19 Oct 22
8-K
Maravai LifeSciences Announces CEO Leadership Transition
3 Oct 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
8-K
Maravai Lifesciences Reports Second Quarter 2022 Financial Results
4 Aug 22
UPLOAD
Letter from SEC
28 Jul 22
CORRESP
Correspondence with SEC
12 Jul 22
UPLOAD
Letter from SEC
29 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
16 May 22
10-Q
2022 Q1
Quarterly report
6 May 22
8-K
Maravai Lifesciences Reports First Quarter 2022 Financial Results
5 May 22
DEF 14A
Definitive proxy
14 Apr 22
10-K
2021 FY
Annual report
1 Mar 22
8-K
Maravai Lifesciences Reports Fourth Quarter and Full Year 2021 Financial Results and Updates 2022 Financial Guidance
23 Feb 22
8-K
Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides
28 Jan 22
8-K
Entry into a Material Definitive Agreement
20 Jan 22
8-K
Other Events
3 Jan 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
8-K
Maravai Lifesciences Reports Third Quarter Financial Results, Updates 2021 Financial Guidance and Provides Preliminary Revenue Guidance for 2022
10 Nov 21
424B4
Prospectus supplement with pricing info
13 Sep 21
EFFECT
Notice of effectiveness
10 Sep 21
Latest ownership filings
4
ANDREW BURCH
16 Apr 24
4
REBECCA BUZZEO
18 Mar 24
4
KURT ORESHACK
18 Mar 24
4
Christine Dolan
18 Mar 24
4
Peter Michael Leddy
18 Mar 24
4
Kevin Herde
18 Mar 24
4
CARL HULL
18 Mar 24
SC 13G/A
12 West Capital Management LP
28 Feb 24
4
KURT ORESHACK
20 Feb 24
4
Kevin Herde
20 Feb 24
4
Christine Dolan
20 Feb 24
4
CARL HULL
20 Feb 24
SC 13G
12 West Capital Management LP
15 Feb 24
SC 13G
12 West Capital Management LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
MARAVAI LIFE SCIENCES HOLDINGS 2, LLC
8 Feb 24
4
ANDREW BURCH
18 Jan 24
4
WILLIAM E. MARTIN III
18 Jan 24
4
Peter Michael Leddy
18 Jan 24
4
KURT ORESHACK
18 Jan 24
4
Kevin Herde
18 Jan 24
4
CARL HULL
18 Jan 24
4
Christine Dolan
18 Jan 24
4
REBECCA BUZZEO
18 Jan 24
5
ANDREW BURCH
18 Jan 24
SC 13G/A
MILLENNIUM MANAGEMENT LLC
5 Jan 24
4
Peter Michael Leddy
16 Nov 23
4
Kevin Herde
16 Nov 23
4
Christine Dolan
16 Nov 23
4
REBECCA BUZZEO
16 Nov 23
SC 13G/A
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
7 Nov 23
SC 13G
MILLENNIUM MANAGEMENT LLC
26 Oct 23
4
WILLIAM E. MARTIN III
17 Oct 23
4
WILLIAM E. MARTIN III
22 Aug 23
4
John A DeFord
21 Jul 23
3
John A DeFord
20 Jul 23
4
Kevin Herde
19 Jul 23
4
KURT ORESHACK
19 Jul 23
4
Christine Dolan
19 Jul 23
4
Jessica Hopfield
19 Jul 23